XML 64 R40.htm IDEA: XBRL DOCUMENT
v3.25.4

Fair Value of Financial Instruments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Fair Value Disclosures [Abstract] |
Schedule of Fair Value of Financial Assets | The following tables present the Company’s fair value hierarchy for its financial instruments that are measured at fair value on a recurring basis (in thousands):
As of December 31, 2025 | Total |  | Quoted prices in active markets (Level 1) |  | Significant other observable inputs (Level 2) |  | Significant unobservable inputs (Level 3)
Financial assets: |  |  |  |  |  |  |
Cash equivalents: (1) |  |  |  |  |  |  |
Money market funds | $ | 17,219 |  |  | $ | 17,219 |  |  | $ | — |  |  | $ | — |
Total cash equivalents | 17,219 |  |  | 17,219 |  |  | — |  |  | — |
Marketable securities: |  |  |  |  |  |  |
Commercial paper | 12,877 |  |  | — |  |  | 12,877 |  |  | — |
U.S. Treasuries | 29,650 |  |  | — |  |  | 29,650 |  |  | — |
U.S. Government agency bonds | 13,594 |  |  | — |  |  | 13,594 |  |  | — |
Corporate bonds | 32,272 |  |  | — |  |  | 32,272 |  |  | — |
Total marketable securities | 88,393 |  |  | — |  |  | 88,393 |  |  | — |
Total financial assets | $ | 105,612 |  |  | $ | 17,219 |  |  | $ | 88,393 |  |  | $ | — |
Financial liabilities: |  |  |  |  |  |  |
Contingent liabilities (2) | $ | 5,684 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,684 |
Total financial liabilities | $ | 5,684 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,684 |
As of December 31, 2024 | Total |  | Quoted prices in active markets (Level 1) |  | Significant other observable inputs (Level 2) |  | Significant unobservable inputs (Level 3)
Financial assets: |  |  |  |  |  |  |
Cash equivalents: (1) |  |  |  |  |  |  |
Money market funds | $ | 44,426 |  |  | $ | 44,426 |  |  | $ | — |  |  | $ | — |
Total cash equivalents | 44,426 |  |  | 44,426 |  |  | — |  |  | — |
Marketable securities: |  |  |  |  |  |  |
Commercial paper | 1,494 |  |  | — |  |  | 1,494 |  |  | — |
U.S. Treasuries | 61,857 |  |  | — |  |  | 61,857 |  |  | — |
U.S. Government agency bonds | 93,978 |  |  | — |  |  | 93,978 |  |  | — |
Corporate bonds | 75,084 |  |  | — |  |  | 75,084 |  |  | — |
Total marketable securities | 232,413 |  |  | — |  |  | 232,413 |  |  | — |
Total financial assets | $ | 276,839 |  |  | $ | 44,426 |  |  | $ | 232,413 |  |  | $ | — |
(1)Included in cash and cash equivalents on the Consolidated Balance Sheets. (2)The Company's recurring fair value measurements using Level 3 inputs related to the Company's contingent consideration liability from the acquisition of Emission and the contingent liability assumed in the acquisition of Akoya.
Schedule of Fair Value, Liabilities Measured on Recurring Basis | The following table presents the changes in the Company's Level 3 financial instruments measured at fair value on a recurring basis, which consist of contingent liabilities:
| Level 3 Liabilities
| Emission (1) |  | PKI License (2) |  | Total
Balance as of December 31, 2024 | $ | — |  |  | $ | — |  |  | $ | — |
Acquisition | 6,612 |  |  | 3,619 |  |  | 10,231 |
Change in fair value of contingent liabilities | (4,624) |  |  | 77 |  |  | (4,547) |
Balance as of December 31, 2025 | $ | 1,988 |  |  | $ | 3,696 |  |  | $ | 5,684 |
(1)Earnout 2 requires additional consideration to be paid to the selling shareholders based on the amount and timing of certain performance targets. Earnout 2 is measured and paid over a five year period ending December 2029. (2)As part of Akoya's 2018 acquisition of the Quantitative Pathology Solutions division of Perkin Elmer, Inc., subsequently known as Revvity, Inc. ("PKI"), Akoya entered into a license agreement with PKI (the "PKI License") (refer to Note 16 - Commitments and Contingencies). The Company recognizes the assumed contingent liability at fair value in accordance with ASC 805. The PKI License is measured and paid over the remaining eight year period ending March 2033.

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration